Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC): First-and second-line data from the BOLERO-4 study.

Affiliation auteurs!!!! Error affiliation !!!!
TitreEverolimus (EVE) plus endocrine therapy in patients with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC): First-and second-line data from the BOLERO-4 study.
Type de publicationJournal Article
Year of Publication2017
AuteursCardoso F, Villanueva C, Royce M, Cruz F, Debled M, Hegg R, Toyama T, Falkson CIsadora, Jeong J, Srimuninnimit V, Ozguroglu M, Gradishar WJohn, Azevedo SJ, Arce CH, Ridolfi A, Lin C, Bachelot TDenis
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume35
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2017.35.15_suppl.1010